A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Glintborg, B; Sorensen, IJ; Loft, AG; Lindegaard, H; Linauskas, A; Hendricks, O; Hansen, IMJ; Jensen, DV; Manilo, N; Espesen, J; Klarlund, M; Grydehoj, J; Dieperink, SS; Kristensen, S; Olsen, JS; Nordin, H; Chrysidis, S; Pedersen, DD; Sorensen, MV; A

Glintborg, B (reprint author), Rigshosp, Ctr Rheumatol & Spine Dis, Ctr Head & Orthopaed, Glostrup, Denmark.

ANNALS OF THE RHEUMATIC DISEASES, 2017; 76 (8): 1426

Abstract

Objectives According to guidelines, a nationwide non-medical switch from originator (INX, Remicade) to biosimilar infliximab (Remsima, CT-P13) was con......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索